NEW YORK (GenomeWeb News) – Beckman Coulter plans to acquire diagnostics company Biosite for about $1.55 billion in cash, the companies said this weekend.
 
Under the deal, Beckman would pay $85 a share for all of Biosite’s common stock, which closed at $55.38 on the Nasdaq Friday.
 
Beckman, which expects the acquisition will increase its footprint in the immunoassay market, said the deal came from a four-year relationship between the companies based on a test that for coronary syndromes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.